Published in J Clin Pathol on March 17, 2011
ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics (2012) 1.74
CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis. PLoS One (2014) 1.45
Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer (2014) 1.10
Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. PLoS One (2014) 1.07
EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer. Br J Cancer (2013) 1.04
Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer (2012) 1.03
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol (2013) 0.91
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas. J Clin Pathol (2014) 0.91
Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo. Mol Pharm (2013) 0.87
Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer. Int J Mol Sci (2013) 0.84
Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. Neuro Oncol (2011) 0.84
Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). J Proteome Res (2012) 0.83
Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Sci Rep (2016) 0.82
Overexpression of eIF3a in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy Response. J Oncol (2012) 0.82
Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream(®) for Detecting (or Monitoring) the Expression of Folate Receptor Alpha. Biomark Insights (2016) 0.82
Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer. Br J Cancer (2011) 0.82
Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis. Cancers (Basel) (2013) 0.82
By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis. Oncotarget (2015) 0.81
MMTV/LTR Promoter-Driven Transgenic Expression of EpCAM Leads to the Development of Large Pancreatic Islets. J Histochem Cytochem (2015) 0.81
Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines. PLoS One (2013) 0.81
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. BMC Cancer (2013) 0.81
MMP7 is a target of the tumour-associated antigen EpCAM. Int J Exp Pathol (2012) 0.80
Circulating tumor cell detection in high-risk non-metastatic prostate cancer. J Cancer Res Clin Oncol (2014) 0.80
Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro. BMC Cancer (2015) 0.79
Using aptamers to elucidate esophageal cancer clinical samples. Sci Rep (2015) 0.78
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget (2016) 0.78
Cancer stem cells in hepatocellular carcinoma - an immunohistochemical study with histopathological association. Indian J Med Res (2015) 0.78
Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy. Int J Mol Sci (2015) 0.78
The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer. PLoS One (2013) 0.78
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients. Oncotarget (2016) 0.78
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins. Biomark Cancer (2016) 0.77
Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget (2017) 0.77
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary. J Cancer Res Clin Oncol (2012) 0.77
EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study. Int J Mol Sci (2016) 0.75
Perinodular ductular reaction/epithelial cell adhesion molecule loss in small hepatic nodules. World J Gastroenterol (2014) 0.75
Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. Oncotarget (2015) 0.75
Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma. Oncotarget (2016) 0.75
Clinicopathology of EpCAM and EGFR in Human Epithelial Ovarian Carcinoma. Open Med (Wars) (2017) 0.75
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol (2009) 4.05
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
EpCAM (CD326) finding its role in cancer. Br J Cancer (2007) 2.98
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res (2004) 2.78
The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene (2004) 2.67
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer (2010) 2.43
Molecular biomarker analyses using circulating tumor cells. PLoS One (2010) 2.38
Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet (1982) 2.25
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet (2000) 1.94
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol (2005) 1.69
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer (2004) 1.58
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res (2004) 1.46
Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma (2010) 1.34
Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res (2008) 1.28
Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol (2006) 1.23
Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs (2010) 1.19
EpCAM expression in normal, non-pathological tissues. Front Biosci (2008) 1.16
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol (2009) 1.12
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett (2006) 1.07
Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer. Cancer Res (1990) 1.05
EpCAM expression in squamous cell carcinoma of the oral cavity: frequency and relationship to clinicopathologic features. Oral Oncol (2007) 0.89
Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol (2009) 4.05
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res (2006) 2.26
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica (2008) 2.16
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
Cytology as an alternative to frozen section at the time of nephron-sparing surgery to evaluate surgical margin status. Urology (2013) 2.04
Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest (2007) 1.97
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol (2005) 1.83
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica (2006) 1.66
TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol (2007) 1.63
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res (2004) 1.46
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
Proteomic profiling of acute cardiac allograft rejection. Transplantation (2009) 1.44
Estradiol enhances murine cardiac allograft rejection under cyclosporin and can be antagonized by the antiestrogen tamoxifen. Transplantation (2002) 1.44
Tetrahydrobiopterin protects the kidney from ischemia-reperfusion injury. Kidney Int (2010) 1.41
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood (2009) 1.37
Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma (2010) 1.34
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol (2009) 1.31
25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem (2004) 1.30
Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol (2002) 1.27
Sebaceous carcinoma of the eyelid: a rarity worth considering. Br J Ophthalmol (2002) 1.27
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol (2004) 1.26
The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A (2005) 1.23
Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol (2010) 1.21
Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod Pathol (2005) 1.20
Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer (2006) 1.18
High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol (2006) 1.18
Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol (2009) 1.17
Neuroendocrine tumors and second primary malignancy--a relationship with clinical impact? Anticancer Res (2004) 1.16
Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun (2007) 1.16
14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res (2005) 1.15
Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer (2002) 1.13
Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol (2011) 1.12
Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch (2002) 1.12
Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation (2007) 1.07
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett (2006) 1.07
Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer (2004) 1.05
Characterization of antigen-presenting cells in fresh and cultured human corneas using novel dendritic cell markers. Invest Ophthalmol Vis Sci (2007) 1.05
Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer (2012) 1.03
Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol (2003) 1.03
Distant metastasis of parotid gland tumors. Acta Otolaryngol (2006) 1.02
Kupffer cells modulate iron homeostasis in mice via regulation of hepcidin expression. J Mol Med (Berl) (2008) 1.01
Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer (2011) 1.00
Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol (2009) 1.00
Retrospective evaluation of carcinoid tumors of the appendix in children. World J Surg (2002) 0.97
RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol (2005) 0.97
Bilirubin inhibits tumor cell growth via activation of ERK. Cell Cycle (2007) 0.96
Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol (2007) 0.95
Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. Int J Cancer (2011) 0.95
Functional sphincter ani externus reconstruction for treatment of fecal stress incontinence using free latissimus dorsi muscle transfer with coaptation to the pudendal nerve: preliminary experimental study in dogs. J Reconstr Microsurg (2007) 0.95
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev (2014) 0.95
The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol (2009) 0.93
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol (2012) 0.93
Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer. Ann Surg Oncol (2012) 0.92
Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. Int J Cancer (2006) 0.92
Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase. J Clin Pathol (2006) 0.92
Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation (2003) 0.92
The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis. Mol Cancer (2009) 0.91
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas. J Clin Pathol (2014) 0.91
Tissue microarray technology: principles, pitfalls and perspectives--lessons learned from hematological malignancies. Exp Gerontol (2005) 0.91
Survival signaling by C-RAF: mitochondrial reactive oxygen species and Ca2+ are critical targets. Mol Cell Biol (2008) 0.90
Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology (2013) 0.90
Short term protective effects of iron in a murine model of ischemia/reperfusion. Biometals (2006) 0.90
STAT1 activation in squamous cell cancer of the oral cavity: a potential predictive marker of response to adjuvant chemotherapy. Cancer (2007) 0.90
EpCAM expression in squamous cell carcinoma of the oral cavity: frequency and relationship to clinicopathologic features. Oral Oncol (2007) 0.89
High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer (2014) 0.89
Tetrahydrobiopterin compounds prolong allograft survival independently of their effect on nitric oxide synthase activity. Transplantation (2006) 0.88
High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol (2003) 0.88
Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin Cancer Res (2006) 0.88
eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cell Oncol (Dordr) (2014) 0.88
Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J Infect Dis (2004) 0.88
(68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging (2014) 0.88
Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res (2007) 0.87
Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res (2008) 0.87
Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis. BMC Cancer (2005) 0.87
EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth. Mol Cancer (2013) 0.87